Carotid artery stenosis
Conditions
Interventions
Continuous treatment continued for a certain period of time Administration group to which EPA is not administered (40 cases).
EPA group (40 patients) who newly added 1800 mg / day of a high-purity EPA
Sponsors
Tokyo Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Carotid artery plaque has been confirmed, patients undergoing cerebral neurosurgery CEA 2. Patients who are taking statins diagnosed as dyslipidemia 3. Patients taking antiplatelet drugs 4. Patients aged between 20 and 85
Exclusion criteria
Exclusion criteria: 1. Patients with a history of hypersensitivity to high-purity EPA preparations 2. Omega-3 fatty acid preparation (Rotriga)/Patient taking EPA preparation 3. Bleeding patients (hemophilia, capillary vulnerability, gastrointestinal bleeding, urinary tract hemorrhage, hemoptysis, vitreous hemorrhage etc.) 4. People with peptic ulcer 5. Other patients who are considered inappropriate by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Tissue fatty acid fraction EPA / AA ratio, DHA / AA ratio 2)Tissue inflammatory cell evaluation CD68 3)echo examination Carotid echo | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Blood data including blood lipids TG, LDL-Chol, HDL-Chol, T-Chol, non-HDL-Chol, AST, ALT, ALP, total bilirubin, total protein, albumin, BUN, Cre, eGFR, Na, K, Cl 2)Blood fatty acid fraction EPA / AA ratio, DHA / AA ratio 3)blood inflammation marker hs-CRP PTX 3 | — |
Countries
Japan
Contacts
Public ContactTatsuya Ishikawa
Tokyo Women's Medical University Neurosurgery
Outcome results
None listed